# Data Analyst and Verification Specialist

### Education:

- **PhD in Biostatistics and Vascular Biology** - University of Sydney, Sydney, Australia. Focus on atherosclerosis and metabolomics.
- **Bachelor of Science (Hons)** - Western Sydney University, Sydney, Australia. Specialized in data analysis and statistical modeling.

### Professional Experience:

- **Senior Data & Verification Specialist at NuvoAir AB, Stockholm, Sweden (Feb 2022 - Present):** Leading data management and programming for clinical trials, ensuring data integrity, and executing data-driven strategies across departments. Expert in statistical analysis, project data management, and working with multifunctional teams in analytics and product verification/validation processes.

- **Clinical Trials Project Associate (Aug 2021 - Feb 2022):** Managed client projects, ensuring high-quality, timely, and within-budget trial execution. Working with operations analysis, client communication, risk management, and project documentation.

- **Postdoctoral Researcher at Uppsala Universitet, Uppsala, Sweden (Mar 2017 – Aug 2021):** Focused on vascular biology and large data analysis, employing quantitative methods to explore complex datasets.

### Skills:

- **Programming & Data:** SQL and Python, with professional experience in data analytics and web development with Django.
- **Serverless Experience:** AWS (ETL/warehousing/analysis), Databricks.
- **Visualization & Reporting:** Knowledge in Matplotlib, Seaborn, Plotly. 
- **Statistical Analysis & A/B Testing:** Proficient in Google Optimize and Optimizely for A/B testing and analysis.
- **Project/Product Management:** Experienced with Atlassian tools for effective project management.

### Publications

1. **Endothelial VEGFR2-PLCγ signaling regulates vascular permeability and antitumor immunity through eNOS/Src.**  
   Sjöberg E, Melssen M, Richards M, Ding Y, Chanoca C, Chen D, Nwadozi E, Pal S, **Love DT**, Ninchoji T, Shibuya M, Simons M, Dimberg A, Claesson-Welsh L.  
   J Clin Invest. 2023 Oct 16. 
   [DOI: 10.1172/JCI161366](https://doi.org/10.1172/JCI161366)

2. **Paladin is a phosphoinositide phosphatase regulating endosomal VEGFR2 signalling and angiogenesis.**  
   Nitzsche A, Pietilä R, **Love DT**, Testini C, Ninchoji T, Smith RO, Ekvärn E, Larsson J, Roche FP, Egaña I, Jauhiainen S, Berger P, Claesson-Welsh L, Hellström M.  
   EMBO Rep. 2021 Feb 3. 
   [DOI: 10.15252/embr.202050218](https://doi.org/10.15252/embr.202050218)

3. **eNOS-induced vascular barrier disruption in retinopathy by c-Src activation and tyrosine phosphorylation of VE-cadherin.**  
   Ninchoji T, **Love DT**, Smith RO, Hedlund M, Vestweber D, Sessa WC, Claesson-Welsh L.  
   Elife. 2021 Apr 28.  
   [DOI: 10.7554/eLife.64944](https://doi.org/10.7554/eLife.64944)

4. **The role of the myeloperoxidase-derived oxidant hypothiocyanous acid (HOSCN) in the induction of mitochondrial dysfunction in macrophages.**  
   **Love DT**, Guo C, Nikelshparg EI, Brazhe NA, Sosnovtseva O, Hawkins CL.  
   Redox Biol. 2020 Sep.
   [DOI: 10.1016/j.redox.2020.101602](https://doi.org/10.1016/j.redox.2020.101602)

5. **Cellular targets of the myeloperoxidase-derived oxidant hypothiocyanous acid (HOSCN) and its role in the inhibition of glycolysis in macrophages.**  
   **Love DT**, Barrett TJ, White MY, Cordwell SJ, Davies MJ, Hawkins CL.  
   Free Radic Biol Med. 2016 May.  
   [DOI: 10.1016/j.freeradbiomed.2016.02.016](https://doi.org/10.1016/j.freeradbiomed.2016.02.016)

6. **Comparative reactivity of myeloperoxidase-derived oxidants with mammalian cells.**  
   Rayner BS, **Love DT**, Hawkins CL.  
   Free Radic Biol Med. 2014 Jun. 
   [DOI: 10.1016/j.freeradbiomed.2014.03.004](https://doi.org/10.1016/j.freeradbiomed.2014.03.004)
